Scott Richard Floyd

Scott Richard Floyd is the Gary Hock and Lyn Proctor Associate Professor of Radiation Oncology at Duke University School of Medicine, with secondary appointments as Associate Professor of Radiation Oncology and Assistant Research Professor in Pharmacology and Cancer Biology. He is also a Member of the Duke Cancer Institute and serves as Associate Radiation Director of the Duke Center for Brain and Spine Metastasis and Associate Program Director of the Duke Radiation Oncology Residency Program.

Dr. Floyd received his M.D. and Ph.D. from Yale University in 2002. His professional training includes:

• Internship in Internal Medicine at Hospital of Saint Raphael (2002-2003)
• Residency in Radiation Oncology at Harvard Medical School, Harvard Radiation Oncology Program (2003-2007)
• Clinical Investigator position at MIT Koch Institute for Integrative Cancer Research (2012-)

Dr. Floyd's research focuses on DNA damage signaling and repair in brain tumor cells, particularly investigating how chromatin changes mediated by epigenetic modifiers affect the DNA damage response (DDR). His lab develops small animal irradiation techniques and mouse models of glioblastoma to test the effects of epigenetic writers and readers on DDR in clinically relevant model systems. He aims to identify strategies to enhance tumor cell killing while protecting normal brain tissues from radiation damage. His work on brain slice models provides a platform for studying stroke, Alzheimer's disease, Huntington's disease, and brain tumors while reducing animal use.

Analysis of Dr. Floyd's recent publications reveals a strong focus on brain metastases, radiation necrosis, and the application of artificial intelligence in radiation oncology. His work increasingly integrates radiogenomics, machine learning, and novel radiation techniques to improve outcomes for patients with brain tumors. There's a clear trend toward interdisciplinary collaboration, particularly in combining radiation therapy with immunotherapy and targeted agents, as evidenced by his leadership in the Consortium for Intracranial Metastasis Academic Research (CIMARa).

Dr. Floyd has secured significant research funding, including:

• NEUROD1 function in SCLC fate and plasticity (NIH, 2024-2029)
• Synthetic lethality with BET bromodomain inhibition (American Cancer Society, 2025-2026)
• ASPET SURF Institutional Award (2018-2028)
• Multiple NIH R01 grants supporting his research on DNA damage response and brain tumor biology

Dr. Floyd leads the Floyd Lab, which focuses on studying mechanisms of DNA damage signaling and repair in brain tumor and other mammalian cells. His lab utilizes advanced techniques including small animal irradiation, mouse models of glioblastoma, and organotypic brain slice culture platforms. He is also involved in Project Brainslice, which develops experimental model systems using brain slices to research new treatments for brain diseases. His clinical expertise centers on the treatment of benign, primary, and metastatic tumors of the brain and spine, making him a key figure in Duke's brain and spine metastasis program.